By Fineline Cube 
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to proceed with two Phase II clinical trials for its in-house developed bispecific antibody drug conjugate (ADC) BL-B01D1. The trials will evaluate BL-B01D1 in combination therapies for gynecological cancers.
Clinical Trial Details
One trial will assess BL-B01D1 combined with pembrolizumab with or without bevacizumab and/or chemotherapy in patients with recurrent or metastatic cervical cancer. The second trial will evaluate BL-B01D1 combined with pembrolizumab with or without chemotherapy in patients with advanced or recurrent endometrial cancer.
Pipeline Highlight
Biokin’s lead ADC candidate, BL-M11D1, is currently the only EGFR×HER3 bispecific ADC in Phase III development globally. It is being evaluated in nearly 40 clinical studies across over 10 tumor types in China and the U.S., further underscoring the company’s commitment to innovative cancer therapies.-Fineline Info & Tech